1. Home
  2. IONS vs HXL Comparison

IONS vs HXL Comparison

Compare IONS & HXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IONS
  • HXL
  • Stock Information
  • Founded
  • IONS 1989
  • HXL 1946
  • Country
  • IONS United States
  • HXL United States
  • Employees
  • IONS N/A
  • HXL N/A
  • Industry
  • IONS Biotechnology: Pharmaceutical Preparations
  • HXL Major Chemicals
  • Sector
  • IONS Health Care
  • HXL Industrials
  • Exchange
  • IONS Nasdaq
  • HXL Nasdaq
  • Market Cap
  • IONS 6.0B
  • HXL 5.1B
  • IPO Year
  • IONS 1991
  • HXL N/A
  • Fundamental
  • Price
  • IONS $34.34
  • HXL $59.47
  • Analyst Decision
  • IONS Buy
  • HXL Hold
  • Analyst Count
  • IONS 18
  • HXL 14
  • Target Price
  • IONS $62.00
  • HXL $71.62
  • AVG Volume (30 Days)
  • IONS 1.1M
  • HXL 923.8K
  • Earning Date
  • IONS 11-06-2024
  • HXL 10-21-2024
  • Dividend Yield
  • IONS N/A
  • HXL 1.01%
  • EPS Growth
  • IONS N/A
  • HXL N/A
  • EPS
  • IONS N/A
  • HXL 1.30
  • Revenue
  • IONS $803,067,000.00
  • HXL $1,886,700,000.00
  • Revenue This Year
  • IONS N/A
  • HXL $8.05
  • Revenue Next Year
  • IONS $16.31
  • HXL $8.64
  • P/E Ratio
  • IONS N/A
  • HXL $45.94
  • Revenue Growth
  • IONS 30.57
  • HXL 7.14
  • 52 Week Low
  • IONS $34.24
  • HXL $57.50
  • 52 Week High
  • IONS $54.44
  • HXL $77.09
  • Technical
  • Relative Strength Index (RSI)
  • IONS 26.91
  • HXL 42.57
  • Support Level
  • IONS $37.18
  • HXL $60.88
  • Resistance Level
  • IONS $40.07
  • HXL $62.54
  • Average True Range (ATR)
  • IONS 1.38
  • HXL 1.38
  • MACD
  • IONS -0.26
  • HXL -0.12
  • Stochastic Oscillator
  • IONS 1.58
  • HXL 23.95

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

About HXL Hexcel Corporation

Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in commercial aerospace, defense, and other industrial markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and its respective subcontractors.

Share on Social Networks: